Compare Moderna, Inc. (MRNA) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Exxon Mobil Corporation — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Exxon Mobil Corporation trades at $168.94 (market cap $692.86B). The key difference: Exxon Mobil Corporation is far larger — about 8.8× Moderna, Inc.'s market cap, and Exxon Mobil Corporation pays a 2.45% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Exxon Mobil Corporation for 99 Days on average.
| MRNA | XOM | |
|---|---|---|
Market Cap | $78.65B | $692.86B |
Volume | 37,373,437 | 13,225,996 |
Sector | Health | Energy |
52-Week High | $225.00 | $171.52 |
52-Week Low | $22.36 | $110.64 |
Typical Hold Time | 59 Days | 99 Days |
Enterprise Value | $74.80B | $724.64B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
Exxon Mobil (XOM) trades at $168.56, up 2.74% today, with a bullish technical signal from moving averages and a consensus analyst price target of $166.67. Recent earnings show mixed results, with a Q2 2026 miss but beats in prior quarters. Revenue has declined from $398.7B in 2022 to $323.9B in 2025, though 2026 projects a rebound to $361.1B. News highlights potential investment in Venezuela's oil fields and expansion in Guyana and the Permian Basin.
XOM presents a stable investment with a 12.55% ROE and dividend yield, but faces risks from volatile oil prices and geopolitical ventures. Analyst sentiment is mixed with 36.36% buy ratings, indicating cautious optimism amid execution risks and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
